 Procedure for Analysis and Interpretation of the Safety Data: The monitoring entity will be Benjamin Wallisch, MD. He will oversee the research participants safety, monitor for unanticipated problems involving risks to participants or others, and assure that such events are reported to the IRB. Integrity and appropriate handling confidentiality of the following data will be monitored: Demographic and morphometrics data, vital signs, bispectral BIS index values, infusion pump flow rate, and recording of occurrence and severity of drug side effects. Monitoring will occur after every study patient is enrolled. Should unexpected adverse events occur. All effort will be made to identify the source causing the event. Source identification may mandate the temporary halting of the study as well as protocol adjustments e.g. reduction of drug doses. Serious adverse events will be reported by Benjamin Wallisch, MD within 2 business days. Serious adverse events will be brought to the attention of the IRB within 24 hours. 